Trials / Completed
CompletedNCT01086501
ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients
Efficacy and Safety of an ER-formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients Under Consideration of Quality of Life Parameters
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 225 (actual)
- Sponsor
- Desitin Arzneimittel GmbH · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the observational study is to investigate the safety of oxcarbazepine extended release (ER) during long-term therapy in epileptic patients. In addition, quality of life parameters should be documented if assessed.
Conditions
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2011-07-01
- Completion
- 2012-10-01
- First posted
- 2010-03-15
- Last updated
- 2013-03-01
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01086501. Inclusion in this directory is not an endorsement.